All Programs

Use the tool below to view all available Series

Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CE
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
0.25 credits
- Jennifer R. Brown, MD, PhD
- William Mencia, MD, FACEHP
0.25 credits
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit
Severity Assessment: Can You Pin the Stage on the Patient?
Severity Assessment: Can You Pin the Stage on the Patient?
MinuteCE®
Severity Assessment: Can You Pin the Stage on the Patient?
1.00 program credit
- Jennifer Geremia, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Treat-to-Target: Are We There Yet? 
Treat-to-Target: Are We There Yet? 
MinuteCE®
Treat-to-Target: Are We There Yet? 
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
MinuteCE®
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
1.00 program credit
- Nancy S. Reau, MD
1.00 program credit
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
MinuteCE®
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
1.00 program credit
- Arun B. Jesudian, MD
1.00 program credit
The Slippery Slope of Overt Hepatic Encephalopathy
The Slippery Slope of Overt Hepatic Encephalopathy
MinuteCE®
The Slippery Slope of Overt Hepatic Encephalopathy
1.00 program credit
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 program credit
MinuteCE®
Clearing the Brain Fog: Innovations in the Treatment and Management of Hepatic Encephalopathy
1.00 credit 9 episodes
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 credit 9 episodes
Hepatic Encephalopathy: More Common Than You Think
Hepatic Encephalopathy: More Common Than You Think
MinuteCE®
Hepatic Encephalopathy: More Common Than You Think
1.00 program credit
- Arun B. Jesudian, MD
1.00 program credit
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
MinuteCE®
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
1.00 program credit
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 program credit
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
CME/CE
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
0.25 credits
- Jose Rubio, MD
0.25 credits
Updates in Major Depressive Disorder with Insomnia
Updates in Major Depressive Disorder with Insomnia
CME/CE
Updates in Major Depressive Disorder with Insomnia
0.50 credits
- Michael E. Thase, MD
- Andrew Krystal, MD
0.50 credits
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits

All Programs

Popular

Title

Share on ReachMD